The strong Phase III data and dual priority review status for wAIHA and ITP NDAs significantly de-risk sovleplenib's regulatory path in China. Monitor NMPA approval decisions and potential label expansion globally, as HUTCHMED retains worldwide rights.
Price Chart
Executive Summary
HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs 15% placebo (p<0.0001) with a favorable safety profile. The NDA for wAIHA was accepted with priority review by China's NMPA in April 2026, and a resubmitted NDA for ITP also received priority review in February 2026. These regulatory milestones and strong efficacy data de-risk the pipeline for a second indication beyond ITP, though no revenue or earnings figures are disclosed.
Key Facts
- Phase III ESLIM-02 met primary endpoint: durable response rate 66% sovleplenib vs 15% placebo (p<0.0001)
- Overall response rate 70% vs 22% (p<0.0001); rescue therapy use reduced to 16% vs 54% (p=0.0001)
- NDA for wAIHA accepted with priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026
- Resubmitted NDA for ITP also granted priority review by NMPA in February 2026
- No TEAE-related deaths or treatment discontinuations in sovleplenib arm; Grade 3 TEAEs 43% vs 59% placebo
- HUTCHMED retains all worldwide rights to sovleplenib
Financial Impact
No revenue or financial figures disclosed; potential peak sales for sovleplenib in wAIHA and ITP in China are not quantified in the filing
Risk Factors
- Regulatory approval in China is not guaranteed despite priority review
- Commercial adoption depends on pricing, reimbursement, and competition from existing steroids and rituximab
- Global expansion outside China would require additional clinical trials and regulatory submissions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000039 |
| Document: hcm-20260612x6k.htm | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index-headers.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039.txt | 0001648257-26-000039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.20 (+0.64%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.20 (+17.16%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.20 (+12.34%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.20 (+13.06%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.20 (+13.06%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.20 (+31.85%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.20 (+24.13%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.20 (+31.97%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.20 (+31.97%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.20 (+32.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access